Research Comparison
Cagrilintide (AM833) vs Mazdutide (IBI362 / LY3305677)
A side-by-side research comparison of Cagrilintide (AM833) and Mazdutide (IBI362 / LY3305677) drawn from Cobalt Peptides' peptide database records.
Cagrilintide (AM833)
Cagrilintide (AM833) is a long-acting, lipidated amylin analogue with activity at both amylin and calcitonin receptors. Its acylation gives an extended half-life suited to once-weekly administration in study protocols, and it has been investigated both alone and alongside GLP-1 receptor agonists in published metabolic research. Cagrilintide is not an approved medicine and remains investigational. Supplied strictly as a research compound for laboratory use.
Mazdutide (IBI362 / LY3305677)
Mazdutide (IBI362 / LY3305677) is a synthetic analogue of oxyntomodulin acting as a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist. Unlike GLP-1-only or GIP/GLP-1 compounds, it engages the glucagon receptor as well, a mechanism examined in the published literature for its distinct contribution to energy balance. Mazdutide is not an approved medicine and remains in clinical development. Supplied strictly as a research compound for laboratory use.